COVID-19 in transplant recipients: the Spanish experience

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Coll, Elisabeth
• dc.contributor.author Crespo Barrio, Marta
• dc.contributor.author Domínguez-Gil, Beatriz
• dc.contributor.author Spanish Group for the Study of COVID-19 in Transplant Recipients
• dc.date.accessioned 2021-05-19T07:29:50Z
• dc.date.available 2021-05-19T07:29:50Z
• dc.date.issued 2021
• dc.description.abstract We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR]: 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR: 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-β (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR]: 2.5; 95% CI: 1.4-4.6), age >60 years (OR: 3.7; 95% CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95% CI: 1.9-4.9).
• dc.format.mimetype application/pdf
• dc.identifier.citation Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, et al. COVID-19 in transplant recipients: the Spanish experience. Am J Transplant. 2021 May; 21(5): 1825-37. DOI: 10.1111/ajt.16369
• dc.identifier.doi http://dx.doi.org/10.1111/ajt.16369
• dc.identifier.issn 1600-6135
• dc.identifier.uri http://hdl.handle.net/10230/47594
• dc.language.iso eng
• dc.publisher Wiley-Blackwell
• dc.rights This is the pre-peer reviewed version of the following article: Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, et al. COVID-19 in transplant recipients: the Spanish experience. Am J Transplant. 2021 May; 21(5): 1825-37, which has been published in final form at http://dx.doi.org/10.1111/ajt.16369. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Antibiotic
• dc.subject.keyword Antiviral
• dc.subject.keyword Clinical decision-making
• dc.subject.keyword Clinical research/practice
• dc.subject.keyword Complication
• dc.subject.keyword Infectious
• dc.subject.keyword Infection and infectious agents - viral
• dc.subject.keyword Infectious disease
• dc.title COVID-19 in transplant recipients: the Spanish experience
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion